If i may opine on why we are different (whilst acknowleding its aim and biotech So of course you can lose the lot. 1. For a chance of shitloads you need it to be scaleable. Which means Patent protection and royalties. This rules out mist services businesses. 2. Mass market. 3. Is it an area of research validated by experts. As an exame Efamol. Patented everything to do with fatty acids. No one else did Because it turned out to be a duff area. Similarly summit and c-diff Looks like a great product with unmet need. No one seems Interested. By contrast several big boys have chased chk1 and Tyk2 and failed. 4. Quality of partnerships. Im an amateur. Do the experts hook Up on the research who know their area in detail. Cruk. Icr. SRI are Undoubtedly. 5. Best in class. It really is winner takes it all. The drug with least Side effects vs competitor wins. BMS dropped out of lung cancer This weekend because opdivo is no better than keytruda after Billions spent. Chk1 seems to be better so far. Tyk2 seems better But vernalis have a chk1 inhibitor available to licence for several Years with no takers (i assume its not better). Lots of uk bios have also ran products. Or research in areas the Mainstream arent that interested in. Frquently they concert to become services businesses to extend Their shelf life. But this is a pure IP play. And a bet that the molecules are in fact Best in class. Our master patent is already referenced by 27 patents from other Companies including takeda. Millenium. Gsk. Incyte. Acertas Nimbus. So the science looks good. And the commercial interest is in our Area. But of course its higher risk and not for widows or orphans
I believe SAR will come good. I have 2 millions shares so I really hope they do but I will be happy with 5p a share. If you have time tomorrow, have a surf round some other AIM minnows. Every one of them has a group of investors who think they are invested in the next 100 bagger, the best thing since sliced bread and most of them will lose most of their investment. If you're constantly dreaming of a pound a share then a more realistic 5 or 10p share may be a disappointment, if and when it hopefully comes.
Oil companies and Bio companies are alike in some ways. They view the geo phys make a decision to drill and hope for the best. Most times they lose. We more or less do the same with chemical compounds. Most times we lose - but as Thoth says a small percentage come through and the company multibags !
Hi Every one B.P has 19.473.29 billion shares in issue at a price of 498.35 has we only have 2.645.22 billion shares in issue so looking at that the share price of SAR could go any where from 0.85 to £10 when I first got into dealing in 1998 my first shares was Dana Petroleum I brought them at 2p and sold them at £6. but they went on to £19 a share. Like I keep saying hold tight to your shares load up on the drops if you can. This company IMOP is another Dana Petroleum SAR is a Game Changer the only draw back is we are just going to have to wait. IMOP GLA.
The important thing is: it HAS happened. I think it's possible. Cancer, autoimmune disorders: massive areas. Oceans of human suffering....if FB, Apple and other rubbish can achieve it, anything is possible. Good luck all
Thank you once again. Obviously you are optimistic that we stand a good chance of success, given the scale of your investment...which is clearly based on very through research and considered opinion. I am encouraged by the degree of optimism from the Sar directors who by definition as research scientists would be cautious and reliant on evidence on which to base their opinions. These guys don't seem the type to get caught up in hype or exaggeration....
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.